Top Page
Atlas Arteria
(Sydney:ALX)
Atlas Arteria (ALX) vs. iShares MSCI Australia ETF (EWA)
Atlas Arteria Business Overview & Revenue Model
Atlas Arteria Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 114.15M | 145.00M | 134.00M | 118.24M | 100.52M | 104.56M |
| Gross Profit | 40.90M | 138.70M | 16.40M | 116.00K | -9.05M | -13.55M |
| EBITDA | 70.45M | 106.30M | 425.70M | 63.07M | -11.95M | -93.68M |
| Net Income | 214.70M | 335.90M | 323.50M | 266.96M | 163.70M | -99.21M |
Balance Sheet | ||||||
| Total Assets | 7.96B | 8.26B | 8.04B | 8.33B | 5.22B | 5.27B |
| Cash, Cash Equivalents and Short-Term Investments | 290.40M | 351.50M | 305.30M | 521.66M | 229.39M | 260.34M |
| Total Debt | 1.70B | 1.85B | 1.72B | 1.74B | 1.65B | 1.55B |
| Total Liabilities | 1.84B | 1.95B | 1.81B | 1.84B | 1.72B | 1.63B |
| Stockholders Equity | 6.12B | 3.34B | 6.24B | 6.49B | 3.50B | 3.63B |
Cash Flow | ||||||
| Free Cash Flow | 430.55M | 92.10M | 712.80M | 473.14M | 38.56M | 24.00M |
| Operating Cash Flow | 431.45M | 93.20M | 84.70M | 473.50M | 40.03M | 25.44M |
| Investing Cash Flow | -1.20M | 633.00M | 631.70M | -3.01B | 304.05M | -976.67M |
| Financing Cash Flow | -680.20M | -683.80M | -682.10M | 2.58B | -374.71M | -232.73M |
Atlas Arteria Technical Analysis
Atlas Arteria Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | AU$1.33B | 24.25 | 5.78% | 3.59% | 9.52% | -8.76% | |
| ― | AU$2.14B | 23.92 | 8.17% | 5.19% | 13.19% | 14.79% | |
| ― | $7.08B | 30.20 | 3.78% | 8.10% | 9.78% | 0.19% | |
| ― | $10.79B | 15.43 | 7.44% | 2.01% | 2.89% | -14.66% | |
| ― | €7.77B | 68.59 | 3.82% | 2.23% | 28.47% | -50.19% | |
| ― | $6.00B | 20.25 | 7.03% | 4.58% | 3.01% | -23.84% | |
| ― | $46.72B | 350.47 | 1.24% | 4.32% | -4.30% | -59.47% |
Atlas Arteria Corporate Events
Atlas Arteria reported a 10.9% increase in toll revenue for Q3 2025 compared to the previous year, driven by strong traffic growth across its portfolio and favorable foreign exchange movements. The company also announced the appointment of Kara Lawrence as CEO of Dulles Greenway, bringing significant leadership experience to the role. This leadership change and revenue growth position Atlas Arteria favorably in the market, potentially benefiting stakeholders through improved operational efficiency and strategic leadership.
The most recent analyst rating on (AU:ALX) stock is a Hold with a A$5.50 price target. To see the full list of analyst forecasts on Atlas Arteria stock, see the AU:ALX Stock Forecast page.
Atlas Arteria announced the cessation of 24,464 performance rights due to the lapse of conditional rights, as the conditions were not met or became incapable of being satisfied. This announcement may impact the company’s financial operations and stakeholder interests by potentially affecting employee incentives tied to performance rights.
The most recent analyst rating on (AU:ALX) stock is a Hold with a A$5.50 price target. To see the full list of analyst forecasts on Atlas Arteria stock, see the AU:ALX Stock Forecast page.
Atlas Arteria announced that Chicago Skyway has successfully priced US$325 million in notes through the US Private Placement market, divided into two tranches with maturities in 2038 and 2041. This transaction, which will not increase incremental debt, aims to repay existing notes maturing in February 2026, thereby strengthening Chicago Skyway’s balance sheet and extending its average debt maturity, while maintaining its S&P credit rating at BBB.
The most recent analyst rating on (AU:ALX) stock is a Hold with a A$5.50 price target. To see the full list of analyst forecasts on Atlas Arteria stock, see the AU:ALX Stock Forecast page.
Atlas Arteria has announced the issuance of 32,214 performance rights as part of an employee incentive scheme. These securities are unquoted and are not intended to be listed on the ASX, reflecting the company’s ongoing efforts to incentivize and retain key personnel, potentially impacting its operational efficiency and stakeholder engagement.
The most recent analyst rating on (AU:ALX) stock is a Hold with a A$5.50 price target. To see the full list of analyst forecasts on Atlas Arteria stock, see the AU:ALX Stock Forecast page.
Atlas Arteria has announced a change in the director’s interest, with Ken Daley, a director of Atlas Arteria Limited, acquiring an additional 4,000 ALX ordinary stapled securities through an on-market trade. This acquisition increases his total holdings to 24,000 securities, reflecting a strategic move that could signal confidence in the company’s future performance and potentially impact stakeholder perceptions.
The most recent analyst rating on (AU:ALX) stock is a Hold with a A$5.50 price target. To see the full list of analyst forecasts on Atlas Arteria stock, see the AU:ALX Stock Forecast page.
Atlas Arteria announced a distribution of 20.0 Australian cents per stapled security for the first half of 2025, with payments expected to be made in early October. This distribution reflects the company’s ongoing commitment to providing value to its stakeholders and maintaining its position in the toll road industry.
The most recent analyst rating on (AU:ALX) stock is a Hold with a A$5.50 price target. To see the full list of analyst forecasts on Atlas Arteria stock, see the AU:ALX Stock Forecast page.
Atlas Arteria has announced a new dividend distribution of AUD 0.20 per share, related to the six-month period ending June 30, 2025. The ex-dividend date is set for September 24, 2025, with a record date of September 25, 2025, and payment scheduled for October 7, 2025. This announcement reflects the company’s ongoing commitment to returning value to its shareholders and may influence investor sentiment positively.
The most recent analyst rating on (AU:ALX) stock is a Hold with a A$5.50 price target. To see the full list of analyst forecasts on Atlas Arteria stock, see the AU:ALX Stock Forecast page.
Atlas Arteria has announced the issuance and conversion of 22,879 unquoted equity securities, effective from September 5, 2025. This move signifies a strategic financial adjustment potentially impacting the company’s capital structure and market positioning, reflecting its ongoing efforts to optimize shareholder value and operational efficiency.
The most recent analyst rating on (AU:ALX) stock is a Hold with a A$5.35 price target. To see the full list of analyst forecasts on Atlas Arteria stock, see the AU:ALX Stock Forecast page.
Atlas Arteria has announced a change in the director’s interest notice, specifically regarding Hugh Wehby, a director of ATLAX. The change involves the vesting of restricted stapled securities and rights under the company’s incentive plans, which were initially granted to compensate Mr. Wehby for forfeiting incentives from his previous employer. This adjustment reflects the company’s ongoing commitment to aligning its leadership’s interests with its strategic goals, potentially impacting its operational focus and stakeholder relations.
The most recent analyst rating on (AU:ALX) stock is a Hold with a A$5.35 price target. To see the full list of analyst forecasts on Atlas Arteria stock, see the AU:ALX Stock Forecast page.
Atlas Arteria announced a change in the director’s interest, with Andrew Cook, a director of Atlas Arteria International Limited, acquiring 1,680 additional ALX ordinary stapled securities through an on-market trade. This acquisition increases his total holdings to 46,430 securities, reflecting a continued confidence in the company’s performance and potential growth, which could positively influence stakeholder perceptions and market positioning.
The most recent analyst rating on (AU:ALX) stock is a Buy with a A$5.70 price target. To see the full list of analyst forecasts on Atlas Arteria stock, see the AU:ALX Stock Forecast page.
Atlas Arteria is a global infrastructure company that operates toll road businesses in France, Germany, and the United States, focusing on delivering efficient road experiences and sustainable business practices. The company is listed on the Australian Securities Exchange as a stapled security, combining shares of Atlas Arteria International Limited and Atlas Arteria Limited.
Atlas Arteria has released its Investor Reference Pack for the half year ended 30 June 2025, highlighting its continued focus on delivering value through its toll road operations in France, Germany, and the United States. This release underscores the company’s strategic positioning in the global infrastructure market and its commitment to sustainable business practices, which are likely to have positive implications for its stakeholders.
The most recent analyst rating on (AU:ALX) stock is a Buy with a A$5.70 price target. To see the full list of analyst forecasts on Atlas Arteria stock, see the AU:ALX Stock Forecast page.
Atlas Arteria has released its results presentation for the half year ended 30 June 2025, highlighting its ongoing operations across its international toll road portfolio. The announcement underscores the company’s commitment to maintaining its market position through strategic management and sustainable practices, which is likely to impact stakeholders positively by reinforcing its operational stability and growth potential.
The most recent analyst rating on (AU:ALX) stock is a Buy with a A$5.70 price target. To see the full list of analyst forecasts on Atlas Arteria stock, see the AU:ALX Stock Forecast page.
Atlas Arteria reported a statutory net profit after tax of $73.3 million for the first half of 2025, impacted by a Temporary Supplemental Tax. Despite this, the company saw an 8.1% growth in toll revenue due to toll increases and favorable foreign exchange rates. The company is pursuing growth projects in France and moving forward with litigation and rate applications in North America. The reaffirmation of its 2025 distribution guidance at 40.0 cents per security demonstrates confidence in its financial stability, supported by growing free cash flow.
The most recent analyst rating on (AU:ALX) stock is a Buy with a A$5.70 price target. To see the full list of analyst forecasts on Atlas Arteria stock, see the AU:ALX Stock Forecast page.
Atlas Arteria has released its financial results for the half-year ending June 30, 2025, in compliance with Australian Accounting Standards. The report, which aligns with IFRS standards, is intended to be read alongside the company’s annual financial report for 2024. This release may impact stakeholders by providing insights into the company’s financial health and operational performance, potentially affecting its market positioning and investor confidence.
The most recent analyst rating on (AU:ALX) stock is a Buy with a A$5.70 price target. To see the full list of analyst forecasts on Atlas Arteria stock, see the AU:ALX Stock Forecast page.
Atlas Arteria reported a 10.7% increase in toll revenue for Q2 2025, driven by strong traffic performance and favorable foreign exchange rates. The APRR and Dulles Greenway showed notable traffic growth, while the A79 continued its robust performance. The French government’s support for the concession model, with proposed refinements, underscores the importance of tolls in financing infrastructure, potentially impacting future operations and stakeholder interests.
The most recent analyst rating on (AU:ALX) stock is a Hold with a A$5.55 price target. To see the full list of analyst forecasts on Atlas Arteria stock, see the AU:ALX Stock Forecast page.